ARID1A and endometrioid adenocarcinoma: All mutations in endometrioid carcinomas were nonsense or insertion/deletion mutations, and there was 73% and 50% of ovarian clear-cell carcinoma and endometrioid carcinoma, respectively, with an ARID1A mutation showed a loss of ARID1A expression (Wiegand et al., 2010).